Search

Your search keyword '"Yin, Guowen"' showing total 33 results
Start Over Author "Yin, Guowen"
33 results on '"Yin, Guowen"'

2. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization

Author

Xia, Dongdong, Wang, Qiuhe, Bai, Wei, Wang, Enxin, Wang, Zhexuan, Mu, Wei, Sun, Junhui, Huang, Ming, Yin, Guowen, Li, Hailiang, Zhao, Hui, Zhang, Chunqing, Li, Jing, Wu, Jianbing, Zhu, Xiaoli, Yang, Shufa, Pan, Xingnan, Li, Jiaping, Li, Zixiang, Xu, Guohui, Shi, Haibin, Zhang, Hui, Zhang, Yuelin, Ding, Rong, Yu, Hui, Zheng, Lin, Yang, Xiaohu, Wang, Guangchuan, You, Nan, Feng, Long, Zhang, Shuai, Huang, Wukui, Xu, Tao, Fan, Wenzhe, Li, Xueda, Yang, Xuegang, Zhou, Weizhong, Wang, Wenjun, Li, Xiaomei, Wang, Zhengyu, Luo, Bohan, Niu, Jing, Yuan, Jie, Lv, Yong, Li, Kai, Guo, Wengang, Yin, Zhanxin, Fan, Daiming, Xia, Jielai, and Han, Guohong

Published
2022
Full Text
View/download PDF

3. THU-475 Tumor burden incorporating AFP improves survival prediction for patients with HCC undergoing TACE: an international multicentre observational study

Author

Xia, Dongdong, primary, Bai, Wei, additional, Wang, Qiuhe, additional, Chung, Jin Wook, additional, Adhoute, Xavier, additional, Kloeckner, Roman, additional, Zhang, Hui, additional, Zeng, Yong, additional, Sripongpun, Pimsiri, additional, Nie, Chunhui, additional, Kim, Seung Up, additional, Huang, Ming, additional, Hu, Wenhao, additional, Ding, Xiangchun, additional, Yin, Guowen, additional, Li, Hailiang, additional, Zhao, Hui, additional, Li, Jing, additional, Li, Jiaping, additional, Zhu, Xiaoli, additional, Wu, Jianbing, additional, Zhang, Chunqing, additional, Gong, Weidong, additional, Li, Zixiang, additional, Lin, Zhengyu, additional, Xu, Tao, additional, Yin, Tao, additional, Song, Jinlong, additional, Shi, Haibin, additional, Shao, Guoliang, additional, Ren, Weixin, additional, Zhang, Yongjin, additional, Yang, Shufa, additional, Zheng, Yanbo, additional, Xu, Jian, additional, Wang, Wenhui, additional, Zhu, Xu, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, and Han, Guohong, additional

Published
2024
Full Text
View/download PDF

4. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Author

Ren, Zhenggang, Xu, Jianming, Bai, Yuxian, Xu, Aibing, Cang, Shundong, Du, Chengyou, Li, Qiu, Lu, Yinying, Chen, Yajin, Guo, Yabing, Chen, Zhendong, Liu, Baorui, Jia, Weidong, Wu, Jian, Wang, Junye, Shao, Guoliang, Zhang, Bixiang, Shan, Yunfeng, Meng, Zhiqiang, Wu, Jianbing, Gu, Shanzhi, Yang, Wei, Liu, Chao, Shi, Xuetao, Gao, Zhenyuan, Yin, Tao, Cui, Jiuwei, Huang, Ming, Xing, Baocai, Mao, Yilei, Teng, Gaojun, Qin, Yanru, Wang, Jinhai, Xia, Feng, Yin, Guowen, Yang, Yong, Chen, Mingxia, Wang, Yan, Zhou, Hui, and Fan, Jia

Published
2021
Full Text
View/download PDF

5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE.

Author

Diao, Lingfeng, Wang, Chendong, You, Ran, Leng, Bin, Yu, Zeyu, Xu, Qingyu, Cheng, Yuan, and Yin, Guowen

Subjects
PROGRAMMED cell death 1 receptors, CHEMOEMBOLIZATION, IMMUNE checkpoint inhibitors, ADVERSE health care events, CANCER chemotherapy
Abstract

Background and Aim: The study aims to investigate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and immune checkpoint inhibitors (ICIs) versus lenvatinib and ICIs for hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) refractoriness. Methods: Patients with intermediate or advanced TACE‐refractory HCC who received lenvatinib and ICIs with or without HAIC between 2020 and 2022 were retrospectively reviewed. The tumor response, overall survival (OS), progression‐free survival (PFS), and treatment‐related adverse events (TRAEs) were evaluated and compared between the two groups. Factors affecting OS and PFS were identified with univariate and multivariate Cox regression analyses. Results: A total of 121 patients were enrolled, with 58 patients assigned to the HAIC‐Len‐ICI group and 63 patients assigned to the Len‐ICI group. A higher objective response rate and disease control rate were found in the HAIC‐Len‐ICI group than in the Len‐ICI group (48.30% vs 23.80%, P = 0.005; 87.90% vs 69.80%, P = 0.02, respectively). The median OS was 24.0 months in the HAIC‐Len‐ICI group and 13.0 months in the Len‐ICI group (P = 0.001). The median PFS was 13.0 months in the HAIC‐Len‐ICI group and 7.2 months in the Len‐ICI group (P < 0.001). Multivariable analyses suggested that the presence of cirrhosis, Child–Pugh B stage, and HAIC‐Len‐ICI therapy option were prognostic factors for OS and PFS. The incidences of any grade and grade 3/4 TRAEs were both comparable between the two groups. Conclusions: HAIC combined with lenvatinib and ICIs yielded better OS, PFS, ORR, and DCR than lenvatinib‐ICI therapy in patients with HCC refractory to TACE, with manageable adverse events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Author

Wang, Qiuhe, Xia, Dongdong, Bai, Wei, Wang, Enxin, Sun, Junhui, Huang, Ming, Mu, Wei, Yin, Guowen, Li, Hailiang, Zhao, Hui, Li, Jing, Zhang, Chunqing, Zhu, Xiaoli, Wu, Jianbing, Li, Jiaping, Gong, Weidong, Li, Zixiang, Lin, Zhengyu, Pan, Xingnan, Shi, Haibin, Shao, Guoliang, Liu, Jueshi, Yang, Shufa, Zheng, Yanbo, Xu, Jian, Song, Jinlong, Wang, Wenhui, Wang, Zhexuan, Zhang, Yuelin, Ding, Rong, Zhang, Hui, Yu, Hui, Zheng, Lin, Gu, Weiwei, You, Nan, Wang, Guangchuan, Zhang, Shuai, Feng, Long, Liu, Lin, Zhang, Peng, Li, Xueda, Chen, Jian, Xu, Tao, Zhou, Weizhong, Zeng, Hui, Zhang, Yongjin, Huang, Wukui, Jiang, Wenjin, Zhang, Wen, Shao, Wenbo, Li, Lei, Niu, Jing, Yuan, Jie, Li, Xiaomei, Lv, Yong, Li, Kai, Yin, Zhanxin, Xia, Jielai, Fan, Daiming, and Han, Guohong

Published
2019
Full Text
View/download PDF

9. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance

Author

Zou,Xinhua, Xu,Qingyu, You,Ran, and Yin,Guowen

Subjects
Journal of Hepatocellular Carcinoma
Abstract

Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, People’s Republic of ChinaCorrespondence: Guowen Yin, Tel +86-19868589105, Email jsnjgwy@163.comPurpose: To evaluate the efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor as a second-line therapy for hepatocellular carcinoma after sorafenib resistance.Materials and Methods: The clinical data of 76 patients with hepatocellular carcinoma who were drug-resistant to sorafenib from September 2018 to May 2022 in the tumor intervention department were collected. Among them, 35 patients used TACE combined with regorafenib plus PD-1 inhibitor (TACE-R-P) as second-line treatment, and the remaining 41 patients used TACE combined with regorafenib (TACE-R) as second-line treatment. The mRECIST (modified Response Evaluation Criteria in Solid Tumors) standard was used to evaluate the therapeutic effect. The progression-free survival (PFS) and overall survival (OS) of the two groups were compared. Blood samples were collected before and after treatment to detect the changes in biochemical indicators, and the adverse events (AEs) related to treatment were recorded.Results: A total of 76 patients were included in the study, including 35 patients receiving TACE-R-P treatment and 41 patients receiving TACE-R treatment. Patients in the TACE-R-P group had longer median OS (19.7months vs 15.2months, HR:0.7716, 95% CI:0.4767– 1.2490, P=0.03), longer median PFS (6.3months vs 3.8months, HR:0.6032, 95% CI:0.3727– 0.9763, P=0.0029), higher objective response rate (37.14% vs 19.51%, P=0.001) and higher disease control rate (71.43% vs 48.78%, P=0.001) than those in the TACE-R group. Multivariate analysis showed that Child–Pugh grade (B/A; HR=1.283, 95% CI: 0.623– 1.707, P=0.014), PVTT (Yes/No, HR=1.455, 95% CI: 0.977– 2.038, P=0.018), extrahepatic metastasis (Yes/No, HR=1.766, 95% CI: 1.135– 2.302, P=0.022) and treatment option (TACE-R/TACE-R-P, HR=1.930, 95% CI: 1.461– 2.850, P=0.017) were independent prognostic factors for OS. There was no significant difference in the incidence and severity of AEs between the two groups.Conclusion: TACE-R-P treatment can be more effective than TACE-R treatment for HCC after sorafenib resistance and can be given priority as a second-line treatment for HCC.Keywords: hepatocellular carcinoma, transarterial chemoembolization, regorafenib, sorafenib, PD-1 inhibitor

Published
2023

10. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)

Author

Sun, Hui-Chuan, Zhou, Jian, Wang, Zheng, Liu, Xiufeng, Xie, Qing, Jia, Weidong, Zhao, Ming, Bi, Xinyu, Li, Gong, Bai, Xueli, Ji, Yuan, Xu, Li, Zhu, Xiao-Dong, Bai, Dousheng, Chen, Yajin, Chen, Yongjun, Dai, Chaoliu, Guo, Rongping, Guo, Wenzhi, Hao, Chunyi, Huang, Tao, Huang, Zhiyong, Li, Deyu, Li, Gang, Li, Tao, Li, Xiangcheng, Li, Guangming, Liang, Xiao, Liu, Jingfeng, Liu, Fubao, Lu, Shichun, Lu, Zheng, Lv, Weifu, Mao, Yilei, Shao, Guoliang, Shi, Yinghong, Song, Tianqiang, Tan, Guang, Tang, Yunqiang, Tao, Kaishan, Wan, Chidan, Wang, Guangyi, Wang, Lu, Wang, Shunxiang, Wen, Tianfu, Xing, Baocai, Xiang, Bangde, Yan, Sheng, Yang, Dinghua, Yin, Guowen, Yin, Tao, Yin, Zhenyu, Yu, Zhengping, Zhang, Bixiang, Zhang, Jialin, Zhang, Shuijun, Zhang, Ti, Zhang, Yamin, Zhang, Yubao, Zhang, Aibin, Zhao, Haitao, Zhou, Ledu, Zhang, Wu, Zhu, Zhenyu, Qin, Shukui, Shen, Feng, Cai, Xiujun, Teng, Gaojun, Cai, Jianqiang, Chen, Minshan, Li, Qiang, Liu, Lianxin, Wang, Weilin, Liang, Tingbo, Dong, Jiahong, Chen, Xiaoping, Wang, Xuehao, Zheng, Shusen, and Fan, Jia

Subjects
Review Article, digestive system diseases
Abstract

Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection, a 'conversion therapy' strategy. However, conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed. Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice. Evidence review: Many research centers in China have accumulated significant experience implementing HCC conversion therapy. Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC; however, there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields. In order to summarize and learn from past experience and review current challenges, the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition) was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice. Sixteen consensus statements on the implementation of conversion therapy for HCC were developed. The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.

Published
2022

11. Supplementary Data from Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Author

Xu, Jianming, primary, Shen, Jie, primary, Gu, Shanzhi, primary, Zhang, Yun, primary, Wu, Lihua, primary, Wu, Jian, primary, Shao, Guoliang, primary, Zhang, Yanqiao, primary, Xu, Li, primary, Yin, Tao, primary, Liu, Jingfeng, primary, Ren, Zhenggang, primary, Xiong, Jianping, primary, Mao, Xianhai, primary, Zhang, Ling, primary, Yang, Jiayin, primary, Li, Lequn, primary, Chen, Xiaoming, primary, Wang, Zhiming, primary, Gu, Kangsheng, primary, Chen, Xi, primary, Pan, Zhanyu, primary, Ma, Kuansheng, primary, Zhou, Xinmin, primary, Yu, Zujiang, primary, Li, Enxiao, primary, Yin, Guowen, primary, Zhang, Xiao, primary, Wang, Shuni, primary, and Wang, Quanren, primary

Published
2023
Full Text
View/download PDF

14. Effect of different PD‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.

Author

Lei, Zhengqing, Ma, Weihu, Si, Anfeng, Zhang, Yuhua, Yang, Facai, Yu, Qiushi, Tang, Haolan, Xiao, Qianru, Zhou, Jiahua, Wang, Kui, Tang, Yufu, Han, Tao, Yin, Guowen, Chen, Jinhong, Liu, Xiufeng, Zhao, Hua, Yu, Decai, Luo, Tao, Wang, Qing, and Yan, Maolin

Subjects
PROGRESSION-free survival, CHOLANGIOCARCINOMA, IMMUNE checkpoint inhibitors, PROGRAMMED cell death 1 receptors, SURVIVAL rate, OVERALL survival
Abstract

Summary: Background: Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC). Aim: To compare the effect of different anti‐PD‐1 combination therapies as the first‐line treatments for uICC. Methods: This study included 318 patients who received chemotherapy alone (Chemo), anti‐PD‐1 plus chemotherapy (ICI‐chemo), anti‐PD‐1 plus targeted therapy (ICI‐target) or anti‐PD‐1 plus targeted therapy and chemotherapy (ICI‐target‐chemo) as first line for uICC from 22 centres in China. The primary endpoint was progression‐free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. Results: Patients with ICI‐chemo (median PFS [mPFS], 6.3 months; HR: 0.61, 95% CI: 0.42–0.88; p = 0.008; median OS [mOS], 10.7 months; HR: 0.61, 95% CI: 0.39–0.94; p = 0.026), ICI‐target (7.2 months; HR: 0.54, 95% CI: 0.36–0.80; p = 0.002; 15.8 months; HR: 0.54, 95% CI: 0.35–0.84; p = 0.006) or ICI‐target‐chemo (6.9 months; HR: 0.65, 95% CI: 0.47–0.90; p = 0.009; 14.4 months; HR: 0.47, 95% CI: 0.31–0.70; p < 0.001) achieved better clinical outcomes than those with Chemo (3.8 months; 9.3 months). ICI‐target was not inferior to ICI‐chemo in survival outcomes (HR for PFS: 0.88, 95% CI: 0.55–1.42; p = 0.614; HR for OS: 0.89, 95% CI: 0.51–1.55; p = 0.680). ICI‐target‐chemo yielded similar prognoses as ICI‐chemo (HR for PFS: 1.07, 95% CI: 0.70–1.62; p = 0.764; HR for OS: 0.77, 95% CI: 0.45–1.31; p = 0.328) and ICI‐target (HR for PFS: 1.20, 95% CI: 0.77–1.88; p = 0.413; HR for OS: 0.86, 95% CI: 0.51–1.47; p = 0.583) but resulted in more adverse events (p < 0.001; p = 0.010). Multivariable and propensity score analyses supported these findings. Conclusions: Among patients with uICC, ICI‐chemo or ICI‐target provided more survival benefits than Chemo while achieving comparable prognoses and fewer adverse events than ICI‐target‐chemo. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study

Author

You, Ran, primary, Xu, Qingyu, additional, Wang, Qi, additional, Zhang, Qingqiao, additional, Zhou, Weizhong, additional, Cao, Chi, additional, Huang, Xiangzhong, additional, Ji, Honghai, additional, Lv, Penghua, additional, Jiang, Hao, additional, Lu, You, additional, Jin, Yong, additional, Li, Yongjun, additional, Cheng, Long, additional, Wang, Weidong, additional, Xu, Hao, additional, Zhu, Xiaoli, additional, and Yin, Guowen, additional

Published
2022
Full Text
View/download PDF

16. Optimal Time-point of Response Assessment for Predicting Survival Is Associated With Tumor Burden in Hepatocellular Carcinoma Receiving Repeated Transarterial Chemoembolization

Author

Xia, Dongdong, primary, Wang, Qiuhe, additional, Bai, Wei, additional, Wang, Enxin, additional, Wang, Zhexuan, additional, Mu, Wei, additional, Sun, Junhui, additional, Huang, Ming, additional, Yin, Guowen, additional, Li, Hailiang, additional, Zhao, Hui, additional, Zhang, Chunqing, additional, Li, Jing, additional, Wu, Jianbing, additional, Zhu, Xiaoli, additional, Yang, Shufa, additional, Pan, Xingnan, additional, Li, Jiaping, additional, Li, Zixiang, additional, Xu, Guohui, additional, Shi, Haibin, additional, Zhanf, Hui, additional, Zhanf, Yuelin, additional, Ding, Rong, additional, Yu, Hui, additional, Zheng, Lin, additional, Yang, Xiaohu, additional, Wang, Guangchuan, additional, You, Nan, additional, Feng, Long, additional, Zhang, Shuai, additional, Huang, Wukui, additional, Xu, Tao, additional, Fan, Wenzhe, additional, Li, Xueda, additional, Yang, Xuegang, additional, Zhou, Weizhong, additional, Li, Xiaomei, additional, Luo, Bohan, additional, Lv, Yong, additional, Li, Kai, additional, Guo, Wengang, additional, Yin, Zhanxin, additional, Fan, Daiming, additional, Xia, Jielai, additional, and Han, Guohong, additional

Published
2021
Full Text
View/download PDF

20. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Author

Xu, Jianming, primary, Shen, Jie, additional, Gu, Shanzhi, additional, Zhang, Yun, additional, Wu, Lihua, additional, Wu, Jian, additional, Shao, Guoliang, additional, Zhang, Yanqiao, additional, Xu, Li, additional, Yin, Tao, additional, Liu, Jingfeng, additional, Ren, Zhenggang, additional, Xiong, Jianping, additional, Mao, Xianhai, additional, Zhang, Ling, additional, Yang, Jiayin, additional, Li, Lequn, additional, Chen, Xiaoming, additional, Wang, Zhiming, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Pan, Zhanyu, additional, Ma, Kuansheng, additional, Zhou, Xinmin, additional, Yu, Zujiang, additional, Li, Enxiao, additional, Yin, Guowen, additional, Zhang, Xiao, additional, Wang, Shuni, additional, and Wang, Quanren, additional

Published
2021
Full Text
View/download PDF

22. Optimal time-point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization

Author

Xia, Dongdong, primary, Wang, Qiuhe, additional, Wang, Enxin, additional, Bai, Wei, additional, Wang, Zhexuan, additional, Mu, Wei, additional, Sun, Junhui, additional, Huang, Ming, additional, Yin, Guowen, additional, Li, Hailiang, additional, Zhao, Hui, additional, Zhang, Chunqing, additional, Li, Jing, additional, Wu, Jianbing, additional, Zhu, Xiaoli, additional, Yang, Shufa, additional, Pan, Xingnan, additional, Li, Jiaping, additional, Li, Zixiang, additional, Xu, Guohui, additional, Shi, Haibin, additional, Wang, Wenjun, additional, Niu, Jing, additional, Yin, Zhanxin, additional, Xia, Jielai, additional, and Han, Guohong, additional

Published
2020
Full Text
View/download PDF

24. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study

Author

Wang, Zhexuan, primary, Wang, Enxin, additional, Bai, Wei, additional, Xia, Dongdong, additional, Ding, Rong, additional, Li, Jiaping, additional, Wang, Qiuhe, additional, Liu, Lei, additional, Sun, Junhui, additional, Mu, Wei, additional, Zhao, Hui, additional, Pan, Xingnan, additional, Shao, Guoliang, additional, Zhu, Xiaoli, additional, Yin, Guowen, additional, Shi, Haibin, additional, Wu, Jianbing, additional, Lin, Zhengyu, additional, Yang, Shufa, additional, Liu, Jueshi, additional, Wang, Wenhui, additional, Zhu, Xu, additional, Lv, Yong, additional, Li, Jing, additional, Chen, Hui, additional, Wang, Wenjun, additional, Li, Kai, additional, Yuan, Xulong, additional, Yu, Tanlei, additional, Yuan, Jie, additional, Li, Xiaomei, additional, Niu, Jing, additional, Yin, Zhanxin, additional, Xia, Jielai, additional, Fan, Daiming, additional, and Han, Guohong, additional

Published
2020
Full Text
View/download PDF

26. FRI-468-Identifying optimal candidates for combining transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma: A multicenter observational study

Author

Wang, Enxin, primary, Bai, Wei, additional, Wang, Zhexuan, additional, Xia, Dongdong, additional, Wang, Qiuhe, additional, Huang, Ming, additional, Sun, Junhui, additional, Mu, Wei, additional, Zhao, Hui, additional, Pan, Xingnan, additional, Shao, Guoliang, additional, Zhu, Xiaoli, additional, Yin, Guowen, additional, Shi, Haibin, additional, Wu, Jianbing, additional, Li, Jiaping, additional, Lin, Zhengyu, additional, Yang, Shufa, additional, Liu, Jueshi, additional, Wang, Wenhui, additional, Zhu, Xu, additional, Ding, Rong, additional, Lv, Yong, additional, Chen, Hui, additional, Li, Kai, additional, Niu, Jing, additional, Yin, Zhanxin, additional, Xia, Jielai, additional, Fan, Daiming, additional, and Han, Guohong, additional

Published
2019
Full Text
View/download PDF

27. FRI-467-Optimal time-point of response assessment was associated with tumour burden in patients with unresectable hepatocellular carcinoma undergoing repeated transarterial chemoembolization

Author

Xia, Dongdong, primary, Wang, Enxin, additional, Wang, Qiuhe, additional, Bai, Wei, additional, Wang, Zhexuan, additional, Mu, Wei, additional, Sun, Junhui, additional, Huang, Ming, additional, Yin, Guowen, additional, Li, Hailiang, additional, Zhao, Hui, additional, Zhang, Chunqing, additional, Li, Jing, additional, Wu, Jianbing, additional, Zhu, Xiaoli, additional, Yang, Shufa, additional, Pan, Xingnan, additional, Li, Jiaping, additional, Li, Zixiang, additional, Xu, Guohui, additional, Shi, Haibin, additional, Wang, Wenjun, additional, Niu, Jing, additional, Yuan, Jie, additional, Li, Xiaomei, additional, Lv, Yong, additional, Li, Kai, additional, Yin, Zhanxin, additional, Fan, Daiming, additional, Xia, Jielai, additional, and Han, Guohong, additional

Published
2019
Full Text
View/download PDF

33. AS149 - Optimal time-point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization.

Author

Xia, Dongdong, Wang, Qiuhe, Wang, Enxin, Bai, Wei, Wang, Zhexuan, Mu, Wei, Sun, Junhui, Huang, Ming, Yin, Guowen, Li, Hailiang, Zhao, Hui, Zhang, Chunqing, Li, Jing, Wu, Jianbing, Zhu, Xiaoli, Yang, Shufa, Pan, Xingnan, Li, Jiaping, Li, Zixiang, and Xu, Guohui

Subjects
*CHEMOEMBOLIZATION, *TUMORS, *LIVER transplantation
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results